GlobalData on MSN9h
Disc raises $225.5m as it eyes approval of rare skin disorder drug
Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA earlier this week.
Disc Medicine 4.1M share Secondary priced at $55.00
Jefferies, Leerink, Stifel and Cantor Fitzgerald are acting as joint book running managers for the offering. The deal size was increased to ...